GSA Capital Partners LLP grew its position in shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 39.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 387,258 shares of the biopharmaceutical company’s stock after buying an additional 109,558 shares during the quarter. GSA Capital Partners LLP owned approximately 0.28% of Achillion Pharmaceuticals worth $1,778,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently modified their holdings of the stock. Cambridge Investment Research Advisors Inc. raised its stake in shares of Achillion Pharmaceuticals by 3.6% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 800 shares in the last quarter. Canada Pension Plan Investment Board raised its stake in shares of Achillion Pharmaceuticals by 4.7% in the 1st quarter. Canada Pension Plan Investment Board now owns 35,800 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 1,600 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Achillion Pharmaceuticals by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 457,341 shares of the biopharmaceutical company’s stock valued at $2,100,000 after acquiring an additional 2,850 shares in the last quarter. Bank of Montreal Can raised its stake in shares of Achillion Pharmaceuticals by 6.4% in the 2nd quarter. Bank of Montreal Can now owns 56,715 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 3,410 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of Achillion Pharmaceuticals by 1.8% in the 2nd quarter. Wells Fargo & Company MN now owns 219,647 shares of the biopharmaceutical company’s stock valued at $1,009,000 after acquiring an additional 3,827 shares in the last quarter. 74.11% of the stock is currently owned by institutional investors and hedge funds.

Achillion Pharmaceuticals, Inc. (NASDAQ ACHN) opened at 4.11 on Friday. Achillion Pharmaceuticals, Inc. has a 52 week low of $3.15 and a 52 week high of $9.19. The company has a 50 day moving average price of $4.48 and a 200-day moving average price of $4.20. The company’s market capitalization is $562.09 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting the consensus estimate of ($0.16). During the same period last year, the firm earned ($0.14) EPS. On average, equities analysts anticipate that Achillion Pharmaceuticals, Inc. will post ($0.66) earnings per share for the current fiscal year.

A number of research analysts recently weighed in on the company. BidaskClub raised Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 16th. Robert W. Baird reissued a “neutral” rating and issued a $4.00 price objective (down from $5.00) on shares of Achillion Pharmaceuticals in a research note on Tuesday, September 12th. ValuEngine downgraded Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, September 11th. Chardan Capital cut their price objective on Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 9th. Finally, Maxim Group set a $7.00 price objective on Achillion Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $6.50.

TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/09/23/gsa-capital-partners-llp-increases-stake-in-achillion-pharmaceuticals-inc-achn.html.

Achillion Pharmaceuticals Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Stock Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.